Pyxis Oncology (PYXS)
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) produc...
- Open
- 3.300
- High
- 3.390
- Low
- 3.030
- Prev. Close
- 3.370
- Volume
- 716.27K
- Turnover
- 2.23M
- Avg Price
- 3.116
- Bid/Ask Ratio
- -15.61%
- Amplitude
- 10.68%
- 52wk High
- 5.550
- Volume Ratio
- 0.53
- Turnover Ratio
- 2.43%
Pyxis Oncology Analyst Rating
View moreForecast & Rating
Aug 18, 2026Price forecast
$7.22131.48%
Forecast & RatingStrong buy
10analysts
- Strong buy80.00%
- Buy10.00%
- Hold10.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 day ago, 07:57 AM
Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright
- Tip Ranks · Aug 14 at 12:05 PM
Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target Maintained
- Price Alert · Aug 14 at 06:09 AM
Popular pre-market trades in the US stock market: Pyxis Oncology up 9.97% in pre-market; Aehr Test up 8.27% in pre-market
- Tip Ranks · Aug 14 at 01:01 AM
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value
- Market Beat · Aug 13 at 08:11 PM
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
- PUBT · Aug 13 at 06:17 AM
Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer
